Comparative Study on the Immunogenicity and Efficacy of Different Post-exposure Intramuscular Rabies Vaccination Regimens in China

Objective This study aimed to compare the current Essen rabies post-exposure immunization schedule(0-3-7-14-28)in China and the simple 4-dose schedule(0-3-7-14)newly recommended by the World Health Organization in terms of their safety,efficacy,and protection.Methods Mice were vaccinated according to different immunization schedules,and blood was collected for detection of rabies virus neutralizing antibodies(RVNAs)on days 14,21,28,35,and 120after the first immunization.Additionally,different groups of mice were injected with lethal doses of the CVS-11 virus on day 0,subjected to different rabies immunization schedules,and assessed for morbidity and death status.In a clinical trial,185 rabies-exposed individuals were selected for post-exposure vaccination according to the Essen schedule,and blood was collected for RVNAs detection on days 28and 42 after the first immunization.Results A statistically significant difference in RVNAs between mice in the Essen and 0-3-7-14 schedule groups was observed on the 35th day(P<0.05).The groups 0-3-7-14,0-3-7-21,and 0-3-7-28 showed no statistically significant difference(P>0.05)in RVNAs levels at any time point.The post-exposure immune protective test showed that the survival rate of mice in the control group was 20%,whereas that in the immunization groups was 40%.In the clinical trial,the RVNAs positive conversion rates on days 28(14 days after 4 doses)and 42(14 days after 5 doses)were both 100%,and no significant difference in RVNAs levels was observed(P>0.05).Conclusion The simple 4-dose schedule can produce sufficient RVNAs levels,with no significant effect of a delayed fourth vaccine dose(14–28 d)on the immunization potential.

心电图MVP评分对阵发性心房颤动射频导管消融术术后复发的预测价值

目的探讨阵发性心房颤动(paroxysmal atrial fibrillation,PAF)患者射频导管消融术术前体表心电图MVP评分对术后复发的预测价值。方法选取接受射频导管消融术的PAF住院患者299例为研究对象,根据心房颤动(简称房颤)复发与否分为房颤复发组(n=40)和窦性心律(简称窦律)维持组(n=259)。比较两组间术前MVP评分。通过ROC曲线分析确定MVP评分预测房颤消融术术后复发的最佳截断值,应用MVP评分临界值进行房颤消融术术后复发的生存曲线分析。结果(1)PAF患者消融术术后随访时间22.0(11.0,35.0)月,总体未复发率86.6%;(2)与窦律维持组相比,房颤复发组患者病程长[12.0(3.0,48.0)月vs.36.0(11.5,72.0)月,P<0.05]、术前MVP评分增加[(2.20±0.94)分vs.(3.40±1.12)分,P<0.01)],其余术前指标间差异无统计学意义;(3)单因素Cox回归分析提示,术前MVP评分和病程是影响房颤消融术术后复发的危险因素;多因素Cox回归分析结果显示,高术前MVP评分(OR=2.261,95%CI 1.700~3.007,P<0.01)是PAF消融术术后复发的独立危险因素;(4)PAF患者术前MVP评分预测消融术术后复发的ROC曲线下面积(AUC)为0.76(95%CI 0.674~0.843,P<0.05),最佳截断值为3分,敏感性为63.0%、特异性为85.0%。结论术前心电图MVP评分对PAF患者射频导管消融术术后复发有一定的预测价值。

Autologous hematopoietic stem cell transplantation conditioning regimens and chimeric antigen receptor T cell therapy in various diseases

Conditioning regimens employed in autologous stem cell transplantation have been proven useful in various hematological disorders and underlying malignancies;however,despite being efficacious in various instances,negative consequences have also been recorded.Multiple conditioning regimens were extracted from various literature searches from databases like PubMed,Google scholar,EMBASE,and Cochrane.Conditioning regimens for each disease were compared by using various end points such as overall survival(OS),progression free survival(PFS),and leukemia free survival(LFS).Variables were presented on graphs and analyzed to conclude a more efficacious conditioning regimen.In multiple myeloma,the most effective regimen was high dose melphalan(MEL)given at a dose of 200/mg/m2.The comparative results of acute myeloid leukemia were presented and the regimens that proved to be at an admirable position were busulfan(BU)+MEL regarding OS and BU+VP16 regarding LFS.In case of acute lymphoblastic leukemia(ALL),BU,fludarabine,and etoposide(BuFluVP)conferred good disease control not only with a paramount improvement in survival rate but also low risk of recurrence.However,for ALL,chimeric antigen receptor(CAR)T cell therapy was preferred in the context of better OS and LFS.With respect to Hodgkin’s lymphoma,mitoxantrone(MITO)/MEL overtook carmustine,VP16,cytarabine,and MEL in view of PFS and vice versa regarding OS.Non-Hodgkin’s lymphoma patients were administered MITO(60 mg/m2)and MEL(180 mg/m2)which showed promising results.Lastly,amyloidosis was considered,and the regimen that proved to be competent was MEL 200(200 mg/m2).This review article demonstrates a comparison between various conditioning regimens employed in different diseases.

基于MVP的高职数字图像处理课程项目化教学探索

针对高职院校中数字图像处理课程教学难度大的问题,提出一种基于MVP(Machine Vision Platform)平台的数字图像处理课程教学方案,阐述如何组织和重构课程内容,构建以项目为核心的应用型课程框架,以“工件计数”项目为例,介绍基于MVP平台的“三三三”课程教学实施过程,最后通过教学评价说明教学效果。

SETD2 in cancer:functions,molecular mechanisms,and therapeutic regimens

In recent years,the histone methyltransferase SET domain containing 2(SETD2)has garnered significant attention for its involvement in carcinogenesis.Herein we aim to summarize the research advances regarding SETD2 in tumors,elucidate the role in global epigenetic regulation,highlight potential therapeutic regimens for patients with SETD2 deficiency,and outline future research directions.

Effect of cetuximab plus FOLFOX4 regimen on clinical outcomes in advanced gastric carcinoma patients receiving evidence-based care

BACKGROUND Although chemotherapy is effective for treating advanced gastric carcinoma(aGC),it may lead to an adverse prognosis.Establishing a highly effective and low-toxicity chemotherapy regimen is necessary for improving efficacy and outcomes in aGC patients.AIM To determine the efficacy and safety of cetuximab(CET)combined with the FOLFOX4 regimen(infusional fluorouracil,folinic acid,and oxaliplatin)as firstline therapy for patients with aGC,who received evidence-based care(EBC).METHODS A total of 117 aGC patients who received EBC from March 2019 to March 2022 were enrolled.Of these,60 in the research group(RG)received CET+FOLFOX4 as first-line therapy,whereas 57 in the control group(CG)received FOLFOX4.The efficacy[clinical response rate(RR)and disease control rate(DCR)],safety(liver and kidney dysfunction,leukopenia,thrombocytopenia,rash,and diarrhea),serum tumor marker expression[STMs;carbohydrate antigen(CA)19-9,CA72-4,and carcinoembryonic antigen(CEA)],inflammatory indicators[interleukin(IL)-2 and IL-10],and quality of life(QOL)of the two groups were compared.RESULTS A markedly higher RR and DCR were observed in the RG compared with the CG,with an equivalent safety profile between the two groups.RG exhibited notably reduced CA19-9,CA72-4,CEA,and IL-2 levels following treatment,which were lower than the pre-treatment levels and those in the CG.Post-treatment IL-10 was statistically increased in RG,higher than the pre-treatment level and the CG.Moreover,a significantly improved QOL was evident in the RG.CONCLUSION The CET+FOLFOX4 regimen is highly effective as first-line treatment for aGC patients receiving EBC.It facilitates the suppression of STMs,ameliorates the serum inflammatory microenvironment,and enhances QOL,without increased adverse drug effects.

Correlation between postoperative chemotherapy regimen and survival in patients with resectable gastric adenocarcinoma accompanied with vascular cancer thrombus

BACKGROUND Patients with resectable gastric adenocarcinoma accompanied by vascular cancer thrombus(RGAVCT)have a poor prognosis,with a 5-year survival rate ranging from 18.42%-53.57%.These patients need a reasonable postoperative treatment plan to improve their prognosis.AIM To determine the most effective postoperative chemotherapy regimen for patients with RGAVCT.METHODS We retrospectively collected the clinicopathological data of 530 patients who un-derwent radical resection for gastric cancer between January 2017 and January 2022 and who were pathologically diagnosed with gastric adenocarcinoma with a choroidal cancer embolus.Fur-thermore,we identified the high-risk variables that can influence the prognosis of patients with RGAVCT by asse-ssing the clinical and pathological features of the patients who met the inclusion criteria.We also assessed the significance of survival outcomes using Mantel-Cox univariate and multivariate analyses.The subgroups of pa-tients with stages Ⅰ,Ⅱ,and Ⅲ disease who received single-,dual-,or triple-drug regimens following surgery were analyzed using SPSS 25.0 and the ggplot2 package in R 4.3.0.RESULTS In all,530 eligible individuals with RGAVCT were enrolled in this study.The median overall survival(OS)of patients with RGAVCT was 24 months,and the survival rates were 80.2%,62.5%,and 42.3%at 12,24,and 59 months,respectively.Preoperative complications,tumor size,T stage,and postoperative chemotherapy were identified as independent factors that influenced OS in patients with RGAVCT according to the Cox multivariate analysis model.A Kaplan-Meier analysis revealed that chemotherapy had no effect on OS of patients with stage Ⅰ or Ⅱ RGAVCT;however,chemotherapy did have an effect on OS of stage Ⅲ patients.Stage Ⅲ patients who were treated with chemotherapy consisting of dual-or triple-agent regimens had better survival than those treated with single-agent regimens,and no significant difference was observed in the survival of patients treated with chemo-therapy consisting of dual-or triple-agent regimens.CONCLUSION For patients with stage Ⅲ RGAVCT,a dual-agent regimen of postoperative chemotherapy should be recom-mended rather than a triple-agent treatment,as the latter is associated with increased frequency of adverse events.

Clinical Effects of the Follicular Phase Long Regimen and Luteal Phase Long Regimen on Ovulation Induction in IVF-ET Treatment: A Meta-Analysis

Objective:To systematically evaluate the clinical effects of the follicular phase long regimen and the luteal phase long regimen on ovulation induction in IVF-ET treatment.Methods:Databases including PubMed,Embase,Cochrane Library,CNKI,Chinese Biomedical Literature(CBM),VIP,Wanfang,and others were searched up to January 2021.Clinical studies on ovulation induction using the follicular phase long regimen and luteal phase long regimen in IVF-ET treatment were identified.Literature screening,data extraction,and quality evaluation were conducted based on inclusion and exclusion criteria.Meta-analysis was performed using RevMan 5.3 software.Results:After screening,a total of 11 studies were included,comprising 21,544 patients:9,974 in the follicular phase long regimen group and 11,570 in the luteal phase long regimen group.The meta-analysis results were as follows:(1)The number of Gn days and the total amount of Gn in the follicular phase long regimen were higher than those in the luteal phase long regimen(P<0.05);(2)The number of eggs obtained in the follicular phase long regimen was higher than that in the luteal phase long regimen(P<0.05).There were no significant differences in the rate of embryo optimization and cycle cancellation between the two groups(P>0.05);(3)The embryo implantation rate and clinical pregnancy rate in the follicular phase long regimen were higher than those in the luteal phase long regimen(P<0.05),while the abortion rate in the follicular phase long regimen was lower than that in the luteal phase long regimen(P<0.05).Conclusion:Compared to the luteal phase long regimen,the follicular phase long regimen involves more Gn days and a higher total amount of Gn.The optimal embryo rate and cycle cancellation rate were similar between the regimens,but the follicular phase long regimen resulted in more eggs,significantly improved the implantation and clinical pregnancy rates,and reduced the abortion rate.However,these conclusions require further validation through more multicenter,large-sample RCT studies.

MVP和TVP治疗晚期非小细胞肺癌的前瞻随机研究

目的 评价MVP和TVP两种方案治疗晚期非小细胞肺癌的有效率、毒性和生存期。方法 66例晚期非小细胞肺癌随机分为两组 ,MVP组 3 2例 ,TVP组 3 4例 ,两组患者资料相似。MVP组 :丝裂霉素(MMC) 6～ 8mg/m2 ,静注 ,第 1天 ;长春花碱酰胺 (VDS) 2～ 3mg/m2 ,静滴 ,第 1、8天 ;顺铂 (DDP) 70～ 80mg/m2 ,静滴 ,第 1天或分两天。TVP组 :吡喃阿霉素 (THP) 40～ 5 0mg/m2 ,第 1天 ,VDS和DDP同上。两方案均为一周期 2 1天 ,每例完成 2～ 4周期。结果 MVP组有效率为 3 4% (完全缓解 1例 ,部分缓解 10例 ) ,TVP组有效率为 5 6% (完全缓解 1例 ,部分缓解 18例 ) ,TVP有效率高于MVP组 ,但统计学无意义 ( χ2 =2 .2 69,P=0 .13 2 )。TVP组Ⅲ +Ⅳ度骨髓抑制发生率高于MVP组 ,其中粒细胞抑制有显著性差异 ( 79%与 44 % ,χ2=7.45 8,P =0 .0 0 6)。MVP组与TVP组的中位生存期分别为 12个月与 8个月 ,1年生存率 5 3 %与 2 4% ( χ2=4.943 ,P =0 .0 2 6) ,2年生存率 17%与 6% ,3年生存率 6%与 0。结论 MVP有效率相对较低 ,但血液毒性低 ,患者生存期和生存率高 ,是晚期非小细胞肺癌化疗的合适方案。TVP方案近期有效率高 ,但血液毒性明显 ,与MVP方案比较 。

三参冲剂联合MVP方案治疗中晚期非小细胞肺癌临床研究

目的观察三参冲剂联合MVP化疗方案治疗中晚期非小细胞肺癌的疗效。方法将152例中晚期非小细胞肺癌患者随机分为治疗组(79例)和对照组(73例)。治疗组采用三参冲剂联合MVP化疗方案,对照组单纯采用MVP方案。结果治疗组和对照组的临床受益率(CR+PR+SD)分别为82.3%、64.4%,两组比较,P<0.05;1、2、3年生存率分别为60.8%、42.5%,36.7%、19.0%,17.7%、8.2%(P<0.05);并可减低血液高凝状态,提高患者的细胞免疫功能,缓解化疗药物对血象的影响,改善患者的生活质量。结论三参冲剂联合MVP方案化疗治疗中晚期非小细胞肺癌有较好的疗效。

MVP方案治疗非小细胞肺癌的疗效观察

目的观察ＭＶＰ方案治疗非小细胞肺癌（ＮＳＣＬＣ）的治疗效果和毒性反应。方法４５例非小细胞肺癌患者使用ＭＶＰ（ＭＭＣ＋ＶＤＳ＋ＤＤＰ）方案治疗。结果４５例患者中２１例有效，有效率为４６７％。分析诸因素对疗效的影响发现病期早较病期晚疗效好。生活质量评估Ｋａｒｎｏｆｓｋｙ评分升高为６８９％。骨髓抑制为剂量限制性毒性，白细胞下降７５６％无其他严重毒副反应发生。结论ＭＶＰ方案是治疗非小细胞肺癌有效且可以耐受的方案。

MVP化疗同步结合放疗治疗晚期非小细胞肺癌的临床疗效

目的 评价MVP(丝裂霉素、长春地辛和顺铂 )方案化疗同步结合放疗治疗晚期非小细胞肺癌的临床疗效。方法 62例由细胞学或病理证实、初治、KPS评分 60分以上、预计生存时间 3个月以上的ⅢB期或Ⅳ期非小细胞肺癌患者 ,采用信封抽签法分为放化疗组和MVP组各 3 1例。两组患者都接受MVP化疗 ,丝裂霉素 6mg/m2 静脉注射 ,第 1天 ;长春地辛 2mg/m2 静脉注射 ,第 1、8天 ;顺铂 80～ 10 0mg/m2 静脉滴注。每三周重复。放化疗组放射治疗与化疗同时进行 ,照射剂量为 46～ 5 6Gy/5～ 6周。 结果 两组患者接受化疗 2～ 4个周期。放化疗组和MVP组有效率分别为 48.4% (15 /3 1)和 19.4% (6/3 1) (P <0 .0 5 ) ,中位肿瘤进展时间分别为 8个月和 4个月 (P <0 .0 5 ) ,中位生存时间分别为 10个月和 6个月 (P <0 .0 5 ) ,1年生存率分别为 5 4.8% (17/3 1)和 2 2 .6% (7/3 1) (P <0 .0 5 )。放化疗组的骨髓毒性重于MVP组 ,有显著性差异 (P<0 .0 5 ) ;胃肠道反应等两组无显著性差异 (P >0 .0 5 )。结论 MVP化疗同步结合放疗治疗晚期非小细胞肺癌 ,较单纯化疗更能有效地控制肿瘤进展、延长患者的生存时间 ,毒副作用可以耐受。

处理走航式海洋多参数剖面测量系统(MVP)温度和电导率滞后效应的方法

走航式海洋多参数剖面测量系统(moving vessel profiler,MVP)是一种集成程度和自动化程度都较高的海洋调查设备,能对海洋多要素进行同时观测,获得水平方向的高分辨率数据资料。由于温度和电导率传感器响应时间的不匹配,MVP下放速度过快(峰值速度4 m/s)而造成非常明显的盐度尖峰现象。本研究结合Fofonoff(F)法、时间常数指数递归数字滤波(Giles and McDougall,GM)法和Grose提出的盐度尖峰订正方案,提出了一种新的方法,即MCT(match conductivity and temperature response time)法,通过对压力、温度和电导率传感器进行响应时间的匹配来减弱盐度尖峰。将SBE-9型CTD资料作为标准,发现订正后的资料与CTD盐度曲线的互相关系数为0.917,误差比订正前减小80%。对比35°N断面修正前后的盐度资料,订正后温盐跃层处出现的低盐区域消失。MVP的应用比常规海洋调查仪器CTD对于海洋现象的观测更有优势。

CO2激光辅助MVP技术治疗先天性听骨链畸形结果分析

目的应用CO2激光辅助Malleovestibulopexy(MVP)技术治疗先天性听骨链畸形并观察其疗效。方法10例(14耳)先天性听骨链畸形患者,其中6例为单侧传导性聋,4例为双侧传导性聋。14耳均行CO2激光辅助下MVP技术重建听力。通过术前、术后气骨导差比较疗效。手术关键:(1)术中保留锤骨柄完整;(2)以CO2激光行镫骨底板或卵圆窗开窗,直径约为0.6mm;(3)人工听骨置入小窗,并固定于锤骨柄靠近锤骨颈处。结果 14耳先天性听骨链畸形患者中,13例均为镫骨底板固定,1例为前庭窗封闭;其中6耳为砧骨长脚缺失,镫骨上部结构缺失;1耳为砧骨豆状突缺失、镫骨上部结构缺失;1耳为听骨链完整、连接,锤砧关节不活动,砧骨、固定;1耳为听骨链完整、连接,锤砧关节活动,砧骨长脚倾斜度增大;1耳为砧骨缺如,镫骨上结构缺失;2耳为砧骨后倾,长脚压于面神经表面,镫骨上部结构缺失1耳为砧骨长脚缺失,砧骨与镫骨间膜性连接,镫骨上结构存在,镫骨底板固定;还有1耳为砧骨长脚缺失、镫骨上结构畸形伴先天性鼓室胆脂瘤,镫骨底板固定。术前言语频率平均气骨导差为46.5dB,术后言语频率气骨导差平均值为9.71dB,较术前缩小36.79dB(P<0.01);术后患者无恶心、呕吐及明显眩晕。结论镫骨底板固定或封闭伴砧骨缺如或病变的先天性听骨链畸形,采用CO2激光辅助MVP技术可以提高听力,其疗效显著、安全系数高、术后反应轻微。

VIP与MVP方案治疗非小细胞肺癌的对照研究

目的 :通过前瞻性对照研究 ,比较VIP方案与MVP方案治疗晚期非小细胞肺癌的疗效及不良反应。方法 :共 5 3例晚期的非小细胞肺癌患者随机入组 ,治疗组应用VIP方案 (VDS +IFO +DDP) ,对照组应用MVP方案 (MMC +VDS +DDP) ,每例病人至少化疗 2疗程。疗效及不良反应评价均按WHO标准进行 ,每例病人随访生存期。结果 :治疗组中 1例CR ,15例PR ,8例SD ,1例PD ,有效率 (CR +PR)为 6 4 0 % ;对照组中 11例PR ,11例SD ,6例PD ,有效率 (CR +PR)为 3 9 3 %。治疗组有效率比对照组高 ,但无统计学差异 (P =0 0 72 )。治疗组中位生存期为 8个月 ,而对照组为 7月 ,两组无差异 (P >0 0 5 ) ,该组资料目前仍在继续进行随访。两组不良反应均主要为骨髓抑制、恶心呕吐、脱发。Ⅲ +Ⅳ的血白细胞下降治疗组为 5 6 0 % ,对照组为 5 0 0 % ,两组无差异 (P>0 0 5 )。结论 :初步的结果显示VIP方案对于非小细胞肺癌的有效性较高 。

MVP与CAP方案治疗晚期非小细胞肺癌的疗效比较

非小细胞肺癌早期无特征性症状，故确诊时多为Ⅲ～Ⅳ期，失去手术治疗时机，故对晚期非小细胞肺癌的化疗一直令人失望。为了探讨有效的化疗方案，从１９９３年６月至１９９６年１０月我科采用环磷酰胺（ＣＴＸ）、阿霉素（ＡＤＲ）、顺铂（ＤＤＰ）联合（ＣＡＰ方案）和丝...

VP方案与MVP方案治疗非小细胞肺癌的疗效比较

目的：比较ＶＰ方案与ＭＶＰ方案对非小细胞肺癌（ＮＳＣＬＣ）的治疗效果。方法：７８例患者分别用ＶＰ（ＶＤＳ＋ＤＤＰ）方案和ＭＶＰ（ＭＭＣ＋ＶＰ）方案治疗。结果：ＶＰ组和ＭＶＰ组有效率分别为４５７％（１９／４２）和４７２％（１７／３６），两者无显著性差异（Ｐ＞００５）。分析诸因素对疗效的影响发现，病期早较病期晚疗效好。生活质量评估Ｋａｒｎｏｆｓｋｙ评分ＶＰ组升高为７１４％，ＭＶＰ组为６９４％，两组无显著性差异（Ｐ＞００５）。骨髓抑制为限制性毒性，白细胞下降分别为６９０％和７８８％，无其他严重毒副反应发生。结论：治疗非小细胞肺癌。

基于MVP模式的进销存系统的软件架构设计

随着企业信息化的快速进展和网络的日益普及,企业实现基于计算机的进销存系统管理是中小企业普遍关注的热点问题。当前该类软件系统普遍基于两层C/S结构,未解决其业务逻辑的不灵活及安全的问题。该系统结构采用基于MVP模式的三层架构,给出了关键的C#程序代码,后台数据库基于SQLServer2008。实践表明系统的可伸缩性强,使用效果可靠稳定,有一定的实用推广价值。

补肾软坚方与MVP方案联用治疗老年晚期肺癌32例

目的 :研究MVP方案与补肾软坚方联用治疗老年晚期肺癌效果。方法 :以补肾软坚方为主 ,联用MVP方案 ,治疗老年晚期肺癌 32例 (Ⅲ期 17例 ,Ⅳ期 15例 )。结果 :PR15例 ,NC11例 ,PD6例 ,CR +PR占 46 .9% ,1年生存率 49.2 % ,中位生存期 11.9个月。结论 :补肾软坚方与MVP方案联用是治疗老年晚期肺癌比较有效的方案之一。

MVP模式在Android中的应用研究

传统的MVC模式在Android的应用开发中存在诸多不足,主要表现在Android应用开发的关键类Activity会充当Controller和View的合体,既要负责业务逻辑,又要负责显示,造成Activity的职责过多,耦合度高。MVP模式是MVC模式演进而来,引入了Presenter彻底分离Model和View层,在解决Activity臃肿的问题同时,还有助于后期的测试与维护。本文分析MVC对于Android开发的不足,并探索MVP模式在Android开发中的可行性,以及优劣势,最后实现MVP模式在Android开发中的应用。